Evicenter
P&T meetings

Ulixacaltamide

Essential tremor

Regulatory submission
NDA submitted by February 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

3 evidence topics · 3 sources

Human sigma-power biomarker response

“In healthy participants, sigma-power was similarly reduced by 34% to 50% at 10 to 100 mg, with no further reduction at 120 mg.” (opens the source at this quote in a new tab)

Preclinical absence-seizure model

“Z941 and Z944 potently suppressed absence seizures by 85 to 90%” (opens the source at this quote in a new tab)

Experimental Cav1.4 channel modulation

“ML218 and Z944 are dual Cav1/Cav3 modulators of CaV1.4” (opens the source at this quote in a new tab)